Condition
Immune-Mediated Hepatitis clinical trials and research
As of November 12, 2026, Find a Trial lists 5 Immune-Mediated Hepatitis clinical trials that are recruiting, at sites in 5 countries (most in United Kingdom (2), Switzerland (1), France (1)). By phase: Phase 2 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 5Clinical trials
- 5Countries
Newest Immune-Mediated Hepatitis clinical trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| Mycophenolate mofetil with prednisone for immune-related hepatitis from cancer therapy | Phase 2 | Philadelphia, Pennsylvania | Recruiting | Jun 23, 2026 |
| Low-dose prednisolone for immune checkpoint inhibitor–related hepatitis | — | Basel, Canton of Basel-City and 1 other locations | Recruiting | Sep 11, 2025 |
| Identifying blood biomarkers for hepatitis caused by immune checkpoint inhibitors | — | Montpellier, France | Recruiting | Jun 24, 2024 |
| Treatment for liver failure caused by immune checkpoint inhibitors in liver cancer patients | — | Guangzhou, Guangdong | Recruiting | Aug 2, 2022 |
| Liver injury from checkpoint inhibitors | — | Nottingham | Recruiting | Jul 20, 2020 |
All recruiting trials (5)
-
Mycophenolate mofetil with prednisone for immune-related hepatitis from cancer therapy
This study tests whether starting mycophenolate mofetil plus prednisone can help liver inflammation caused by immune checkpoint inhibitors in adults with moderate to severe immune-related hepatitis.
-
Low-dose prednisolone for immune checkpoint inhibitor–related hepatitis
This project will try low-dose prednisolone (0.5–1 mg/kg) to manage grade 2–3 immune-related hepatitis in adults receiving immune checkpoint inhibitors.
-
Identifying blood biomarkers for hepatitis caused by immune checkpoint inhibitors
This study is trying to find specific blood markers in patients who have liver problems caused by immune checkpoint inhibitors to see how they differ from those with regular autoimmune hepatitis.
-
Treatment for liver failure caused by immune checkpoint inhibitors in liver cancer patients
This study is testing a new artificial liver support system to see if it can help liver cancer patients with liver failure caused by certain cancer treatments feel better compared to standard care.
-
Liver injury from checkpoint inhibitors
This project will test whether specific blood, genetic, immune, and liver tissue markers can predict who gets liver injury from checkpoint inhibitors by following people starting these drugs and those who develop liver injury.
Related topics
Quick answers
How many Immune-Mediated Hepatitis clinical trials are recruiting right now?
5, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 5 countries. The most sites are in United Kingdom (2 trials), Switzerland (1 trial), France (1 trial), United States (1 trial), China (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 2: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.